Sagimet director exercises options and sells shares
Sagimet Biosciences Inc. director George Kemble reported an option exercise-and-sale transaction in Series A Common Stock.
Rhea-AI Filing Summary
Sagimet Biosciences Inc. director George Kemble reported an option exercise-and-sale transaction in Series A Common Stock. On August 11, 2026, he exercised stock options covering 20,206 shares at an exercise price of $6.36 per share and received an equivalent number of Series A Common shares. On the same date, he sold 20,206 shares of Series A Common Stock at a weighted average price of $9.9548 per share in multiple trades priced between $9.95 and $9.99. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on August 21, 2025, and that the options involved were fully vested and exercisable as of the transaction date.
Insider Trade Summary 10b5-1
Exercise and Sale: 20,206 shares ($73K approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
Kemble George
Role
Director
Sold
20,206 shs ($201K)
Approx. gross sale proceeds
$201K
Approx. exercise cost
$129K
Approx. pre-tax spread
$73K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F3 | 9,751 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1, F3 | 10,455 | $0.00 | $0.00 |
| Exercise | Series A Common Stock F1 | 9,751 | $6.36 | $62K |
| Exercise | Series A Common Stock F1 | 10,455 | $6.36 | $66K |
| Sale | Series A Common Stock F1, F2 | 20,206 | $9.9548 | $201K |
Holdings After Transaction:
Stock Option (Right to Buy) — 394,050 contracts (Direct);
Series A Common Stock — 62,161 shares (Direct)
Footnotes (3)
- F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $9.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. This option is fully vested and exercisable as of the date hereof.
Key Figures
Shares sold: 20,206 shares
Weighted average sale price: $9.9548 per share
Options exercised: 20,206 shares
+2 more
5 metrics
Shares sold
20,206 shares
Series A Common Stock sale on August 11, 2026
Weighted average sale price
$9.9548 per share
Series A Common Stock sold in multiple transactions between $9.95 and $9.99
Options exercised
20,206 shares
Stock Option (Right to Buy) exercised into Series A Common Stock on August 11, 2026
Option exercise price
$6.36 per share
Exercise price for Stock Option (Right to Buy) into Series A Common Stock
10b5-1 plan adoption date
August 21, 2025
Rule 10b5-1 trading plan governing the reported transactions
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), Series A Common Stock, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Series A Common Stock financial
"underlying_security_title: Series A Common Stock"
Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.
fully vested and exercisable financial
"This option is fully vested and exercisable as of the date hereof."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Sagimet Biosciences (SGMT) director George Kemble report in this Form 4?
George Kemble reported exercising stock options for 20,206 shares of Sagimet Biosciences Series A Common Stock and selling 20,206 shares of Series A Common Stock on August 11, 2026, in an exercise-and-sale transaction.
What was the stock option exercise price reported for Sagimet Biosciences (SGMT)?
The stock options exercised by George Kemble had an exercise price of $6.36 per share, resulting in the acquisition of 20,206 shares of Sagimet Biosciences Series A Common Stock upon exercise on August 11, 2026.
Were George Kemble’s Sagimet Biosciences (SGMT) trades under a Rule 10b5-1 plan?
Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025, indicating they followed a pre-arranged, pre-disclosed trading schedule.
Were the options exercised by George Kemble at Sagimet Biosciences (SGMT) fully vested?
Yes. A footnote explains that the stock option involved in the transactions was fully vested and exercisable as of the date of the reported activity, August 11, 2026, when the options were exercised.
AI-generated analysis. How Rhea-AI works. Not financial advice.
